News | December 05, 2011

Obesity Predicts Higher Quality Of Life Following AF Catheter Ablation

December 5, 2011 – New study shows significant increase in quality of life (QoL) among overweight patients following ablation of atrial fibrillation (AF), compared to patients with a lower body mass index (BMI) where no substantial improvement was observed.  The study, published in the December edition of HeartRhythm, the official journal of the Heart Rhythm Society, reveals an association between BMI and a change in QoL between the pre- and postablation periods in a large AF patient cohort.  The study also verifies comparable procedural success rates of ablation in both overweight and lean patients. 

This study, co-led by Sanghamitra Mohanty, M.D., and Andrea Natale, M.D., at St. David’s Medical Center (SDMC) in Austin, Texas, is the first to use four different assessment tools* to measure QoL in AF patients undergoing catheter ablation, and examined the association between BMI and improvement in QoL scores following ablation in 660 patients.  Patients were categorized into two groups: lean or normal with a normal-BMI (BMI < 25) and overweight or obese with a high-BMI (BMI ? 25), 79 percent of patients had a high-BMI.  Patients were asked to participate in self-administered QoL surveys before and 12 months after the catheter ablation procedure.

While high-BMI patients started with a lower baseline QoL score compared to normal-BMI patients, 12-month postablation QoL scores among the high-BMI group improved significantly in all measures except physical functioning and bodily pain.  Specifically, improvement was observed in role limitations due to physical health (27 percent), role limitations due to emotional problem (22.6 percent) and vitality (21.9 percent).  The high-BMI group also reported reductions in anxiety and depression levels after ablation procedures.  Overall, long-term ablation success was the same in both the normal-BMI group (69 percent) and high-BMI group (63 percent).

“Despite reporting improvement in QoL and comparable procedure-success in obese and overweight patients, this study does not attempt to trivialize the importance of interventions to promote weight loss and adaptation of healthy life style,” said co-lead author Mohanty at SDMC, Austin, Texas. “Obesity still remains a potential risk-factor for AF and many other cardio-vascular diseases and active measures should be taken to reverse this potentially modifiable risk factor.”

*Quality of Life Assessment tools used in the study include, Medical Outcomes Study Short Form-36 (SF-36), Beck Depression Inventory (BDI), Hospital Anxiety and Depression (HAD) scale, and State-Trait Anxiety Inventory (STAI).

For more information: www.hrsonline.org/publications/

 


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now